

bs-0740R**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

CDKN2A/p16-INK4a Rabbit pAb**— DATASHEET —**

Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Reactivity: Human Predicted MW.: 17 kDa Subcellular Location: Cytoplasm ,Nucleus
Clonality: Polyclonal		
GeneID: 1029	SWISS: P42771	
Target: CDKN2A/p16-INK4a		
Immunogen: KLH conjugated synthetic peptide derived from human p16-INK4a: 61-156/156.		
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].		

— VALIDATION IMAGES —

Tissue/cell: human kidney tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-CDKN2A/p16-INK4a Polyclonal Antibody, Unconjugated(bs-0740R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

— SELECTED CITATIONS —

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

- **[IF=11.161]** Cui Yuanbo. et al. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Canc Res. 2021 Dec;40(1):1-20 WB ;human. 34544449
- **[IF=7.068]** Cao M et al. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression. J Exp Clin Cancer Res. 2020 Jun 3;39(1):102. IHC ;Human. 32493454
- **[IF=7.31]** Zhiheng Liao. et al. Dihydroartemisinin Attenuated Intervertebral Disc Degeneration via Inhibiting PI3K/AKT and NF- κ B Signaling Pathways.. OXID MED CELL LONGEV. 2022 Sep;2022:8672969-8672969 IHC ;Rat. 36120596
- **[IF=4.92]** Carreras et al. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. (2014) Slee. 37:1817-24 IHC ;Mouse. 25364077
- **[IF=4.996]** Jiang Jie. et al. Artificial intelligence reveals dysregulation of osteosarcoma and cuproptosis-related biomarkers, PDHA1, CDKN2A and neutrophils. SCI REP-UK. 2023 Mar;13(1):1-16 IHC ;Human. 36967449